4//SEC Filing
INTERCEPT PHARMACEUTICALS INC 4
Accession 0001144204-15-036564
CIK 0001270073operating
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 9:00 PM ET
Size
11.0 KB
Accession
0001144204-15-036564
Insider Transaction Report
Form 4
Adorini Luciano
Chief Scientific Officer
Transactions
- Sale
Common Stock
2015-06-08$250.34/sh−2,000$500,670→ 10,060 total - Sale
Common Stock
2015-06-08$246.46/sh−2,000$492,928→ 12,060 total - Exercise/Conversion
Option to Purchase Common Stock
2015-06-08−4,000→ 67 totalExercise: $8.67Exp: 2021-10-13→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2015-06-08$8.67/sh+4,000$34,667→ 14,060 total
Footnotes (4)
- [F1]The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
- [F2]All the shares underlying this option have fully vested.
- [F3]This transaction was executed in multiple trades at prices ranging from $245.7200 to $246.5700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $250.2400 to $250.4300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001270073
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 9:00 PM ET
- Size
- 11.0 KB